ELAN:NYE-Elanco Animal Health (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 15.02

Change

-0.12 (-0.79)%

Market Cap

USD 7.56B

Volume

3.09M

Analyst Target

USD 26.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.69B
HLN Haleon plc

N/A

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.37B
CTLT Catalent Inc

N/A

USD 10.83B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.67B
BHC Bausch Health Companies Inc

N/A

USD 2.33B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

N/A

USD 2.14M
PRGO Perrigo Company PLC

N/A

N/A

ETFs Containing ELAN

PETZ:LSE 11.16 % 0.00 %

N/A

N/A
KATZ:XETRA 9.20 % 0.00 %

N/A

N/A
PETZ:SW 9.20 % 0.00 %

N/A

N/A
XGLF:F db x-trackers MSCI GCC Se.. 5.83 % 0.00 %

N/A

USD 0.02B
XGLF:XETRA db x-trackers MSCI GCC Se.. 5.83 % 0.00 %

N/A

USD 0.02B
WTD7:F WisdomTree Issuer ICAV - .. 1.37 % 0.00 %

N/A

USD 0.06B
WTES:F WisdomTree Issuer ICAV - .. 1.37 % 0.00 %

N/A

USD 0.06B
WTD7:XETRA WisdomTree Issuer ICAV - .. 1.37 % 0.00 %

N/A

USD 0.06B
WTES:XETRA WisdomTree Europe SmallCa.. 1.37 % 0.00 %

N/A

USD 0.06B
DFE:SW WisdomTree Europe SmallCa.. 1.25 % 0.00 %

N/A

N/A
DFEA:SW WisdomTree Europe SmallCa.. 1.25 % 0.00 %

N/A

N/A
DFE WisdomTree Europe SmallCa.. 0.00 % 0.58 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
XGLF:LSE db x-trackers MSCI GCC Se.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.81% 35% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.81% 35% F 25% F
Trailing 12 Months  
Capital Gain 25.48% 59% D- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.48% 59% D- 78% C+
Trailing 5 Years  
Capital Gain -45.08% 31% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.08% 31% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -4.22% N/A N/A 20% F
Dividend Return -4.22% N/A N/A 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.46% N/A N/A 22% F
Risk Adjusted Return -9.94% N/A N/A 20% F
Market Capitalization 7.56B 58% F 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector